- Biotechnology
- Thursday, 07 May 2020
AUM LifeTech and AUM BioTech Launch "Knockdown Coronavirus" Research Program
The coronavirus pandemic has significantly disrupted life in most countries around the globe, causing a severe health and economic crisis. AUM LifeTech, Inc., a preclinical stage biotech company developing RNA therapeutics, and AUM BioTech, LLC, a genetic research startup, have jointly launched a research program called Knockdown Coronavirus with a goal of developing a treatment for COVID-19. Under this initiative, the two Philadelphia-based companies are offering self-delivering RNA silencing research products, powered by FANA ASO technology, to the global coronavirus research community to facilitate research and fast track therapeutic development.
AUM LifeTech is currently working with collaborators with the goal of developing a therapy for COVID-19. AUM BioTech's next-generation gene silencing research tools have the capability to selectively knockdown RNA of the virus. Further, AUM BioTech's RNA targeting technology can be used to perform high-throughput genetic screening to identify the function of viral and host genes and help identify new targets for COVID-19 therapy development.
"We are very excited to launch this program and serve the global scientific community, which is working tirelessly to find a cure for COVID-19 in these unique and challenging times," said Veenu Aishwarya, founder and chief executive officer of AUM LifeTech, Inc. and AUM BioTech, LLC. "RNA targeting technology works by silencing (knocking down) the RNA that plays a crucial role, causing a loss of function, thus inhibiting viral replication and transmission. We are very proud to offer our RNA silencing platform, to better understand the biology of SARS-CoV-2 and its interaction with the host. Our goal is to provide our expertise and resources to facilitate COVID-19 research with a hope to develop a potential antiviral therapy for COVID-19 using our self-delivering FANA ASO technology. Additionally, we are actively seeking new alliances and invite the scientific community to partner with us to knockdown coronavirus and defeat COVID-19."
Related Industry Updates
Clearsight Advises Cumberland on the Sale of its Life Sciences Division to IntegriChain
Apr 14, 2020
North America Cancer Tissue Diagnostics Market Key Manufacturers, Development Trends and Competitive Analysis by 2027
Sep 17, 2020
Primary Practicability Trial announced by Medtronic
Oct 07, 2019
North America Human Microbiome Market Research Revealing the Growth Rate and Business Opportunities to 2027
Jan 13, 2021
Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair
May 18, 2020
Healthcare Fraud Analytics Market Size 2021 Industry Analysis, Key Players, Growth Prospects, Revenue, Production, New Development, Business Share, Global Trends and Forecast To 2027
Apr 05, 2021
Bioreactors Market is expected to reach US$ 6,570.76 million by 2030
Nov 24, 2023